Compare Inovio Pharmaceuticals Inc (INO) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Oxford Lane Capital Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Oxford Lane Capital Corp trades at $8.56 (market cap $835.71M). The key difference: Oxford Lane Capital Corp is far larger — about 7.4× Inovio Pharmaceuticals Inc's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Oxford Lane Capital Corp for 50 Days on average.
| INO | OXLC | |
|---|---|---|
Market Cap | $112.19M | $835.71M |
Volume | 3,201,278 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $2.60 | $16.66 |
52-Week Low | $0.66 | $8.15 |
Typical Hold Time | 43 Days | 50 Days |
Enterprise Value | $83.51M | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
OXLC trades at $8.53, up 0.83% today, but faces significant fundamental challenges with a negative ROE of -39.16% and recent earnings misses. Technical indicators show a bearish trend with strong selling pressure on moving averages, though RSI suggests potential oversold conditions. The company maintains a consistent $0.20 monthly dividend while navigating substantial net asset value declines reported in recent updates.
The outlook remains cautious with deteriorating fundamentals offset by high dividend yield. Key risks include unsustainable payout ratios and NAV erosion, while potential upside exists if CLO market conditions stabilize. Analyst sentiment is divided with 50% buy ratings but technicals indicate continued downward pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
